Erythromycin tablets are taken by mouth to treat selected bacterial infections, including strep throat, whooping cough, bacterial pneumonia, sinus infection, and some skin infections. Erythromycin can also be chosen when a penicillin antibiotic is unsuitable. It treats susceptible bacterial infections by reducing bacterial protein production, which stops the organisms from multiplying.
Erythromycin tablets are taken by mouth at an individually prescribed dose to treat selected bacterial infections. Erythromycin is a macrolide antibiotic.
Erythromycin is a macrolide antibiotic. It treats susceptible bacterial infections by reducing bacterial protein production, which stops the organisms from multiplying. The choice depends on the suspected bacteria, infection site, local resistance patterns, previous antibiotic exposure, and the patient’s medical history.
Erythromycin may be prescribed for:
Erythromycin does not treat viral illnesses such as ordinary colds or influenza. Using it for a non-bacterial infection adds side-effect risk without treating the cause.
Erythromycin has activity against several Gram-positive bacteria and some atypical respiratory organisms. It has been used for streptococcal pharyngitis, pertussis, and selected bacterial pneumonias. Macrolide resistance varies by region, so treatment selection should follow clinical assessment and relevant UK guidance.
For whooping cough, early antimicrobial treatment can be useful for reducing spread, although symptom improvement may be limited if the cough has already continued for some time. Erythromycin may also be used for close contacts in defined public-health circumstances.
A bacterial sinus infection requires clinical assessment because facial pressure, blocked nasal passages, and coloured discharge can also occur with viral illness. Antibiotic treatment is reserved for cases where bacterial infection is considered likely.
Erythromycin can reduce susceptible bacterial activity in some skin infections. Its use in acne has become more selective because repeated antibiotic exposure can encourage resistance. Topical or oral treatment may be considered within a broader plan that addresses inflammation, blocked pores, and the duration of antibiotic use.
A worsening skin infection, rapidly spreading redness, severe pain, fever, or red streaking requires prompt medical assessment rather than self-treatment with leftover antibiotics.
Erythromycin can activate motilin receptors in the upper gastrointestinal tract. This may increase gastric contractions and promote stomach emptying, which explains its specialised use in some cases of delayed gastric emptying or stomach muscle paralysis.
The same gastrointestinal activity can produce unwanted cramping, nausea, or diarrhoea during antibiotic treatment. The motility effect does not make erythromycin suitable for every digestive complaint.
Erythromycin binds to the 50S subunit of the bacterial ribosome. This interferes with peptide-chain formation, limiting the protein synthesis required for bacterial growth. The result is usually bacteriostatic activity, although effects can vary with the organism, concentration, and infection site.
Penicillin antibiotics act on bacterial cell-wall synthesis. Erythromycin works through a different target, so it can cover some organisms that are not addressed by penicillin. It also has activity against certain atypical respiratory bacteria that lack the conventional cell-wall targets affected by penicillin.
The EMA describes macrolide safety considerations that include gastrointestinal effects, liver reactions, drug interactions, and cardiac electrophysiology. Erythromycin’s ability to inhibit CYP3A4 is clinically relevant because it can raise concentrations of several other medicines [1].
Particular caution or avoidance may apply with:
The MHRA highlights the need to consider cardiac risk and interactions when prescribing macrolides. A complete medicine list should include prescribed drugs, over-the-counter products, and supplements because erythromycin can alter the exposure of medicines that would otherwise be tolerated at their usual dose [2].
Pregnancy and breastfeeding require an individual assessment of infection severity, alternatives, and the selected formulation. Erythromycin has been used during pregnancy when clinically indicated, but interaction and liver considerations remain relevant.
This medicine may not be suitable if you have had a serious allergic reaction to erythromycin or another macrolide. Tell a clinician if you have heart rhythm problems, liver disease, low potassium or magnesium, or take medicines for heart rhythm, cholesterol, blood clotting, migraines, seizures, or immune conditions. Pregnancy and breastfeeding also need an individual medical assessment.
Gastrointestinal symptoms are the most familiar adverse effects of erythromycin. They are linked partly to stimulation of motilin receptors and may occur even when the antibiotic is working against the infection.
Common or recognised effects include:
Hair loss has been reported less commonly than gastrointestinal effects and should be discussed if it appears during treatment or continues afterwards. A mild rash may be allergic, viral, or unrelated, so its timing and appearance matter.
Seek urgent medical attention for facial or throat swelling, breathing difficulty, blistering skin, fainting, severe palpitations, yellowing of the skin, dark urine, or severe watery or bloody diarrhoea. Erythromycin-associated diarrhoea can rarely reflect Clostridioides difficile infection, which may arise during or after antibiotic treatment.
Erythromycin can prolong the QT interval and increase the risk of a serious rhythm disturbance in susceptible people. The risk rises with certain heart conditions, low potassium or magnesium, and other QT-prolonging medicines.
The active substance is erythromycin, a macrolide antibiotic supplied in oral tablet formulations. Different erythromycin salts, esters, and release designs can affect absorption, stomach tolerance, and dosing frequency. The prescribed formulation should be used as directed because products containing the same antibiotic are not always interchangeable on a tablet-for-tablet basis.
The amount per intake is set individually rather than being one fixed dose for every person. The prescriber selects the dose, frequency, formulation, and course length according to the infection, age, kidney and liver function, interacting medicines, and clinical response.
Key administration points include:
Erythromycin and penicillin belong to different antibiotic classes. Their clinical roles overlap in some respiratory infections, yet their bacterial coverage, interaction profiles, and adverse effects differ.
| Feature | Erythromycin | Penicillin |
|---|---|---|
| Drug class and target | Macrolide; blocks bacterial protein synthesis | Beta-lactam; disrupts bacterial cell-wall formation |
| Typical role | Selected respiratory, skin, atypical, and pertussis infections | First-line treatment for many susceptible streptococcal infections |
| Main limitation | Gastrointestinal intolerance, interactions, cardiac rhythm risk, resistance | Allergy risk and limited activity against atypical organisms |
Penicillin remains a preferred treatment for many cases of streptococcal throat infection when the bacteria are susceptible and the patient can take it. Erythromycin may be selected for a genuine immediate penicillin allergy or when its atypical-organism coverage is clinically useful.
The choice should not be based on allergy wording alone. A mild stomach upset after penicillin is different from facial swelling, breathing difficulty, or anaphylaxis.
Several practical errors can reduce benefit or increase harm:
A practical point is easy to miss: a missed dose should not be “repaired” with a double dose. Extra erythromycin is more likely to worsen nausea and interaction risk than to restore treatment benefit.
In clinical practice, doctors often view erythromycin as a useful macrolide with a narrow margin for casual prescribing. Its advantages include an alternative mechanism to penicillin and activity against selected atypical respiratory organisms. Its limitations include frequent gastrointestinal intolerance, resistance in some bacteria, and a substantial interaction burden.
A physician will usually want to know whether the infection was diagnosed clinically, whether antibiotics were recently used, and whether the patient takes heart medicines, statins, anticoagulants, or migraine medicines containing ergot derivatives. Those details can change the safest choice.
The WHO describes antimicrobial resistance as a major global health concern, making antibiotic selection and course completion important parts of responsible treatment [3]. Erythromycin should be used for a bacterial indication where its expected benefit outweighs its interaction and adverse-effect risks.
A previous serious allergic reaction to erythromycin or another macrolide rules out further use unless a specialist provides a clear alternative plan. A history of erythromycin-related cholestatic jaundice or significant liver injury is another important exclusion. These risks should be reviewed before treatment. The EMA's 2024 product information identifies serious liver reactions and hypersensitivity as clinically relevant safety concerns [4]. A mild stomach upset alone does not prove an allergy, but severe diarrhoea, jaundice, swelling, or breathing difficulty requires urgent assessment.
Yes. Diarrhoea is a recognised adverse effect of erythromycin and may occur because the antibiotic alters intestinal bacteria and can stimulate gastrointestinal motility. Mild loose stools may settle, but severe, persistent, watery, or bloody diarrhoea can indicate Clostridioides difficile infection. NICE antibiotic safety guidance published in 2023 supports prompt assessment when diarrhoea is severe or continues after antibiotic exposure. Avoid self-treating severe diarrhoea with anti-motility medicines before receiving medical advice.
The course length depends on the infection and is set individually rather than by one universal schedule. Short courses are common for acute infections, while specialised gastrointestinal use may follow a different plan and duration. Long-term antibiotic use can increase resistance, diarrhoea, thrush, liver complications, and interaction risk, so it requires a defined clinical reason and review. The British National Formulary (2024) and MHRA safety information support limiting antibiotic exposure to the shortest suitable course for the indication, with reassessment when symptoms fail to improve.
Erythromycin may be prescribed during pregnancy when a clinician considers treatment necessary and suitable alternatives are less appropriate. The choice depends on the infection, gestational stage, maternal conditions, and interaction profile. NHS medicines information from 2024 and EMA regulatory material describe erythromycin use in pregnancy and breastfeeding as a clinical decision rather than an automatic exclusion. Breastfed infants should be observed for diarrhoea, vomiting, rash, or unusual irritability, with medical advice sought if these occur.
Do not split, crush, or chew an erythromycin tablet unless the specific formulation is confirmed to permit it. Enteric-coated or modified-release designs may be damaged by crushing, which can alter absorption and stomach exposure. The MHRA's 2024 guidance advises attention to formulation-specific administration instructions because medicines with the same active substance can behave differently after manipulation. Swallow the tablet whole with water when it is designed for intact administration; a suitable liquid formulation may be considered when swallowing is difficult.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
The cough began settling after several days, but the first part of the course caused stomach cramps and loose stools. Taking the tablets with a light meal helped, although I still finished with some nausea.
The tablets were straightforward to swallow and my throat pain improved. I felt sick after one dose when I took it without food, so I changed the timing after checking that food was suitable for my formulation.
The infection improved, but I noticed palpitations and stopped taking further doses until I received urgent medical advice. I was also taking heart medication, which made the interaction issue relevant in my case.
